The Prospective Study on the Effect of Ilaprazole in Non-erosive Reflux Disease Patients; Focused on Histologic Findings and Inflammatory Biomarker

Inclusion Criteria: * Older than 20 years old and younger than 80 years old * Patients with typical reflux symptoms at least 2days per week (or GERD Q score ≥ 8 ) * No erosion at GE junction through endoscopy * Patients that can perform a 24 hr - combined multichannel intraluminal impedance and pH esophageal monitoring prior to this study. Exclusion Criteria: * included prior history of documented intolerance of ilaprazole or similar PPIs, or * unsuspected alarm symptoms such as weight loss, hematemesis, hematochezia, jaundice or other significant illness like malignancy * alcoholism or drug addiction * uncontrolled diabetes, cerebrovascular accident or diseases needed an operation in the last 3 months before enrollment * any previous esophageal surgery * malignancy in gastrointestinal tract within 5years * pregnant woman * Zollinger-Ellison syndrome, Barrett's esophagus, primary esophageal motility abnormality, esophageal stricture, duodenal ulcer, gastric ulcer, pancreatitis, absorption disorder, severe cardiovascular disease, severe lung disease in the last 3 months before enrollment * history of steadily taking medicine such as diazepam, quinidine, diphenylhydantoin, mephenytoin, warfarin, anticholinergic, prostaglandin analog, antineoplastic agent, salicylate, steroid, pro-motility drug, nonsteroidal anti-inflammatory drugs(NSAIDS) * patients who were registered other exams within 28days * patients who could not conduct sedated endoscopy